top of page
Data Driven AML Treatment
OncoVerity is the fourth spin-off company from argenx's Immunology Innovation Program developed in collaboration with CU Anschutz and UCHealth. The company is working to advance treatments for AML based novel data-driven translational biology insights.
OncoVerity is a CU Anschutz spinout company.
bottom of page